MED.SW up 5.98% to CHF85.10 pre-market on SIX 11 Mar 2026: Watch 17 Mar earnings

The MED.SW stock jumped 5.98% to CHF85.10 in pre-market trading on the SIX on 11 Mar 2026, making it a high-volume mover to watch. Trading accelerated ahead of an earnings announcement on 17 Mar 2026, with volume at 3,279.00 shares versus an average of 4,928.00. We see this move driven by short-term traders and position adjustments ahead of results. This article breaks down price action, valuation, technical signals, the upcoming catalyst, and Meyka AI’s grade and forecast for Medartis Holding AG (MED.SW stock) on the SIX in Switzerland.

Price action and volume: MED.SW stock pre-market movers

MED.SW stock rose from an open of CHF81.00 to a pre-market high of CHF90.50 on 11 Mar 2026, settling at CHF85.10 by the timestamp. The one-day change was +5.98%, with reported volume 3,279.00, below the 30-day average 4,928.00, but notable given the price swing. The jump signals short-term demand and position reshuffling ahead of the March earnings date.

Fundamentals and valuation for Medartis Holding AG (MED.SW)

Medartis Holding AG (MED.SW) lists on the SIX in Switzerland and operates in Medical – Devices. Key metrics show EPS -0.05, PE -1702.00, and a price-to-sales ratio 4.48. Book value per share is CHF21.62 and cash per share is CHF9.97, supporting balance-sheet strength. The company posts a strong gross margin 79.11% but net margin is slightly negative at -0.21%, pointing to narrow after-tax profitability.

Technical setup and trader signals for MED.SW stock

Technically, MED.SW sits below its 50-day average (CHF89.90) and just above its 200-day average (CHF84.30), giving mixed trend cues. RSI is 41.74, MACD histogram is -0.98, and ATR is 3.86, suggesting modest volatility. Bollinger Bands range from CHF82.32 to CHF96.30, so current price is inside the band and near middle support.

Earnings calendar and near-term catalysts for MED.SW earnings

Medartis reports results on 17 Mar 2026 (earnings announcement). That release is the primary catalyst for near-term directional risk. Investors should watch revenue growth, operating margin commentary, and inventory trends. For direct company updates see the Medartis investor site Medartis Investors and the company data summary Company data.

Meyka AI rating and MED.SW stock forecasts

Meyka AI rates MED.SW with a score of 73.75 out of 100, Grade B+, Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects a quarterly target of CHF98.37 and a yearly projection of CHF83.63. Versus the current price CHF85.10, the quarterly projection implies an upside of 15.59% while the yearly model suggests a small downside of -1.78%. Forecasts are model-based projections and not guarantees.

Risks and sector context for MED.SW stock

Medartis operates in Healthcare, where the sector average PE is about 30.19 and average PB is 4.88. MED.SW’s valuation shows a high PB (3.94) and a negative PE reflecting recent earnings patterns. Inventory days are elevated at 641.96, which is a stock-specific operational risk. Debt metrics are moderate with debt-to-equity 0.47, but interest coverage near 0.98 signals sensitivity to margin pressure.

Final Thoughts

MED.SW stock is an active pre-market mover on SIX on 11 Mar 2026 after a +5.98% price move to CHF85.10, driven by short-term positioning ahead of an earnings release on 17 Mar 2026. Fundamentals show strong gross margins, cash per share CHF9.97, and a conservative balance sheet, but earnings remain slightly negative (EPS -0.05) and inventory days are high at 641.96, which raises operational risk. Technically, the stock trades under the 50-day average (CHF89.90) but above the 200-day average (CHF84.30), creating a mixed setup for traders. Meyka AI’s model projects a quarterly target of CHF98.37, implying a 15.59% upside from current price CHF85.10, while the yearly model sits near CHF83.63, a -1.78% variance. We view MED.SW stock as a watchlist candidate for traders who accept earnings volatility and inventory risk. Use the upcoming results as the decisive short-term event; adjust position size and stop-loss levels to account for potential swings. Meyka AI’s analysis is an AI-powered market analysis platform and not investment advice; forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.